sterna biologicals invited to present at the GOODWIN - SOLEBURY TROUT - NASDAQ european biotech investor day 2019

Marburg, Germany, 25 July 2019

  • sterna biologicals selected as one of a group of top-tier European biotech companies to present at the European Biotech Investor Day on August 1, 2019 in New York City
  • CEO Christian Pangratz to discuss the Company’s robust development progress and next phase of growth fueled by sterna’s first-in-class DNAzyme hgd40 in Phase 2 development for asthma and ulcerative colitis

sterna biologicals strengthens management team to progress towards phase IIB development

Marburg, Germany, 08 July 2019

  • Industry veteran Dr. Marion Wencker strengthens sterna’s management team as consulting CMO
  • Financial expert Dr. Thomas Klaue recently joined sterna as consulting CFO

sterna biologicals GmbH & Co. KG (Sterna), an innovative clinical-stage immunology company developing novel biological treatments for chronic inflammatory diseases, announced today that the Company has recently appointed Dr. Marion Wencker as consulting Chief Medical Officer and Dr. Thomas Klaue as consulting Chief Financial Officer.

sterna biologicals prepares for phase IIB clinical program with GATA-3 antagonist drug candidates SB010 in asthma and SB012 in ulcerative colitis

Marburg, Germany, September 05, 2018

  • Key preparatory steps to conduct phase IIb trials initiated, including CMC and regulatory activities in the EU and US
  • Devices for SB010 in asthma selected, oral formulation work for SB012 in ulcerative colitis (UC) started

Sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, today provided an update on its preparations for phase IIb clinical development of its GATA-3 antagonist drug candidates SB010 and SB012.

Successfull device feasibility studies with sterna biologicals asthma drug candidates SB010 enables select of optimal nebulizers for late-stage development and commercialization

Marburg, Germany, September 05, 2018 

  • Feasibility studies show excellent data with SB010 across a selection of high efficiency hand-held nebulizers
  • Company well positioned to advance SB010 into late-stage clinical development

Sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced today that the Company has successfully completed in vitro device feasibility studies with its asthma drug candidate, SB010. These studies support the selection of the most efficient and user-friendly device options for late-stage development and commercialization of SB010.

sterna biologicals presents detailed results from successful phase 2a study with GATA-3 specific DNAzyme formulation SB012 in patients with ulcerative colitis

Marburg, Germany, June 5, 2018

  • Comprehensive data set presented at Digestive Disease Week® in the U.S.
  • SB012 was safe and well tolerated and led to marked clinical and endoscopic improvement in patients with active ulcerative colitis
  • Further support of GATA-3 antagonism as promising treatment approach for variety of chronic inflammatory diseases

sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced that the full data set from the successful SECURE study (NCT 02129439), a Phase 2a trial in patients with moderate to severe ulcerative colitis treated with the GATA-3 specific DNAzyme formulation SB012, was presented during an oral session on June 5th at Digestive Disease Week® in Washington, DC.